Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential teriparatide followed by denosumab versus denosumab alone for prevention of refracture after osteoporotic vertebral fracture
ChiCTR2600134572Phase 4Completed
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of teriparatide and denosumab in osteoporosis and vertebral compression fracture (VCF) (2 arms), sponsored by Shenzhen Nanshan People's Hospital. Primary endpoint: Incidence of new vertebral fractures within 12 months. Started Mar 2024; status: completed.
02
Drugs
teriparatidedenosumab
03
Conditions
osteoporosisvertebral compression fracture (VCF)
Beyond the preview
Go deeper on ChiCTR2600134572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134572.